TMT-based proteomics analysis reveals the efficacy of jiangzhuo formula in improving the lipid profiles of dyslipidemia rats

Journal of Ethnopharmacology
Linlin PanGuirong Liu

Abstract

Jiangzhuo Formula (JZF) is a traditional Chinese herbal prescription that is clinically applied to treat dyslipidemia. However, the mechanism underlying its efficacy remains unexplored. This study aims to elucidate the underlying mechanisms, explore potential pathways, and identify the key proteins of JZF for the treatment of dyslipidemia. In this work, Q-Orbitrap high-resolution liquid chromatography mass spectrometry was used to identify the natural ingredients in JZF, rats with dyslipidemia were established via a high-fat diet for four weeks, then the dyslipidemia rats were treated with high-dose JZF (9 g/d) and low-dose JZF (4.5 g/d) for four weeks. After treatment, serum lipid detection and Oil-red-O staining were conducted to assess the efficacy of JZF in ameliorating dyslipidemia. Tandem mass tag (TMT) -based quantitative proteomics technology was then used to evaluate the roles and importance of proteins from the extracted hepatic tissue. The differentially expressed proteins were assessed by Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, Gene Ontology (GO), and protein-protein interaction (PPI) networks. Western blot and PCR analysis were used to validate the potential targets regulated by JZF. JZF could sign...Continue Reading

References

Jul 1, 1985·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·M PoapstG Steiner
Jun 5, 2002·Annual Review of Biochemistry·Joachim Herz, Hans H Bock
Mar 21, 2007·The American Journal of Cardiology·Michael H DavidsonTerry A Jacobson
May 21, 2009·Journal of Ethnopharmacology·Daih-Huang KuoJuei-Tang Cheng
Dec 17, 2009·Atherosclerosis·Ashish ShahJohn S Millar
Mar 12, 2011·Journal of Cardiovascular Translational Research·Zhu ChenAmy M Flattery
May 9, 2012·Expert Opinion on Drug Safety·Anastazia Kei, Moses S Elisaf
Aug 30, 2012·Journal of Lipid Research·Esther M M OoiP Hugh R Barrett
Aug 6, 2013·Cardiovascular Drugs and Therapy·Amirhossein Sahebkar, Gerald F Watts
Apr 12, 2014·Proteomics·Zachery R Gregorich, Ying Ge
May 30, 2014·Nature·Mathias WilhelmBernhard Kuster
Sep 1, 2014·Neurobiology of Disease·Yadong Huang, Robert W Mahley
Oct 21, 2014·IUBMB Life·Michael C Phillips
Nov 1, 2005·EcoSal Plus·John E Cronan, David Laporte
Apr 19, 2017·Journal of Proteome Research·Christopher S HughesGregg B Morin
Apr 14, 2018·Journal of Lipid Research·Alaa Sirwi, M Mahmood Hussain
Apr 27, 2018·Journal of Pharmaceutical and Biomedical Analysis·Hongyu JiZhimin Du
Aug 24, 2018·Circulation Journal : Official Journal of the Japanese Circulation Society·Maryam ZaidINTERLIPID and INTERMAP Research Groups
Jan 19, 2019·Journal of the American College of Cardiology·Wynn G HunterSvati H Shah
Apr 8, 2019·Lipids in Health and Disease·Ploypun NarindrarangkuraPanadda Hatthachote
Mar 20, 2020·Current Pharmaceutical Biotechnology·Yanchun ZhongLicheng Zhang
Apr 11, 2020·Journal of the American College of Cardiology·Beatriz López-MelgarValentín Fuster

Citations

Feb 27, 2021·Journal of Theoretical Biology·Chong YuJin Wang

Related Concepts

Related Feeds

ApoE Phenotypes

Apolipoprotein E (APOE) is a protein involved in fat metabolism and associated with the pathogenesis of Alzheimer's disease and cardiovascular disease. Here is the latest research on APOE phenotypes.

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.

© 2021 Meta ULC. All rights reserved